Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2, SINGLE-ARM, OPEN-LABEL, MULTICENTER STUDY OF THE CLINICAL ACTIVITY AND SAFETY OF ENZALUTAMIDE IN PATIENTS WITH ADVANCED, ANDROGEN RECEPTOR-POSITIVE, TRIPLE-NEGATIVE BREAST CANCER

NCT01889238 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01889238
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01889238 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2, SINGLE-ARM, OPEN-LABEL, MULTICENTER STUDY OF THE CLINICAL ACTIVITY AND SAFETY OF ENZALUTAMIDE IN PATIENTS WITH ADVANCED, ANDROGEN RECEPTOR-POSITIVE, TRIPLE-NEGATIVE BREAST CANCER
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
June 12, 2013
Completion date
January 10, 2024
Enrollment
118 (actual)
Sites
132

Conditions

As the registry lists them; a condition with its own page is linked.

advanced, androgen receptor positive triple negative breast cancer